Beyond Kill It All
Why aggressive treatment is not always the smartest answer for tiny, slow-growing, or suspected dormant disease
Dormancy biology changes how small residual disease should be interpreted.
It does not mean treatment should be avoided.
It means the most aggressive option is not automatically the most intelligent one.
Experimental and clinical evidence suggests that, in some people, the immune system can hold tiny nests of cancer cells in a long‑term “stand‑off” called immune‑mediated dormancy or the equilibrium phase of cancer immuno-editing. In this state, immune cells (especially CD8 T cells and NK cells) apply just enough pressure to prevent growth but not enough to remove every last cell. Supporting this equilibrium — by protecting immune function, reducing chronic inflammation and stress, and avoiding unnecessary immunosuppression — can sometimes be as important as trying to eliminate every visible cell.
&#xNAN;Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. Vaccines (Basel). 2015;3(3):597–619.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4586469/
Why standard treatment can miss the real problem
Standard chemotherapy is best at killing actively dividing cells.
Dormant and slow-cycling cells often survive that pressure.
This can produce a familiar pattern:
larger, fast-growing lesions shrink
tiny nodules or scattered cells persist
recurrence later comes from the cells that were hardest to hit
Risks of a pure kill-everything approach
A kill-focused strategy can have trade-offs.
Selection pressure
Harsh treatment may remove the most treatment-sensitive cells first.
That can leave behind more stress-tolerant, stem-like, or dormant clones.
Microenvironment disruption
Local and systemic treatment can inflame or remodel the tissue niche.
In some settings, that may favour reactivation rather than long-term control.
Quality-of-life trade-offs
A very small stable lesion may not pose the same immediate risk as another toxic treatment round.
That question becomes more important in heavily pre-treated settings.
How to think about tiny lesions
A small focus on imaging is not just a radiology problem.
It is a systems question.
Ask:
does destroying this focus reduce overall risk?
could the treatment environment wake other dormant cells?
is stability itself an acceptable short-term goal?
Local treatment still has a place
This is not an argument against SBRT, cryoablation, or other focal tools.
It is an argument for using them with a whole-body view of risk.
For members considering aggressive local treatments, dormancy science does not say “never do it.” Instead, it suggests:
Think systemically: local destruction should ideally be paired with strategies that calm the surrounding microenvironment and systemic inflammation, and that support immune surveillance.
Consider whether deep dormancy of a very small, stable lesion might sometimes be an acceptable goal, especially if systemic options have been exhausted or are unlikely to work on slow‑cycling cells.
Explore whether timing (for example, peri-operative beta‑blockade, careful management of infection and pain, staged interventions) could reduce the risk that a big inflammatory event wakes distant dormant cells.
Bottom line
Dormancy science pushes against reflex thinking.
Sometimes the right goal is eradication.
Sometimes the better goal is durable control with less biological disruption.
Key References
Novel Strategies to Combat Dormant Disseminated Tumor Cells
https://pmc.ncbi.nlm.nih.gov/articles/PMC8111294/
Cancer cell dormancy: An update to 2025
https://bmrat.biomedpress.org/index.php/BMRAT/article/download/994/2044
Cellular Dormancy in Cancer: Mechanisms and Potential Targeting
https://pmc.ncbi.nlm.nih.gov/articles/PMC10372609/